Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B003 monotherapy and planned BL-B01D1 + SI-B003 combination therapy in unresectable locally advanced or recurrent/metastatic HER2-negative breast cancer
CTR20232905Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SI-B003, izalontamab brengitecan in breast cancer, sponsored by Biokin Pharmaceutical. Started Dec 2023; status: active.
02
Drugs
SI-B003izalontamab brengitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232905.